Hydroxychloroquine: A double‑edged sword (Review)

Mol Med Rep. 2025 Apr;31(4):102. doi: 10.3892/mmr.2025.13467. Epub 2025 Feb 21.

Abstract

Hydroxychloroquine (HCQ) is an antimalarial drug that has historically been used to treat and prevent malaria. However, its mechanism of action has not yet been fully elucidated. HCQ affects various cellular and molecular pathways through different mechanisms. HCQ has also been shown to be a disease‑improving agent for the treatment of rheumatic diseases, including systemic lupus erythematosus, antiphospholipid syndrome, rheumatoid arthritis and primary Sjögren's syndrome. Although generally considered safe, adverse reactions have been reported with the use of HCQ and clinicians should carefully monitor patients with rheumatism when prescribing these drugs. The purpose of the present review is to strengthen the clinical use of HCQ for autoimmune diseases while highlighting the adverse effects that may occur during treatment.

Keywords: adverse events; hydroxychloroquine; rheumatic disease; toxic effect.

Publication types

  • Review

MeSH terms

  • Animals
  • Antimalarials* / adverse effects
  • Antimalarials* / therapeutic use
  • Antirheumatic Agents* / adverse effects
  • Antirheumatic Agents* / therapeutic use
  • Arthritis, Rheumatoid / drug therapy
  • Autoimmune Diseases / drug therapy
  • Humans
  • Hydroxychloroquine* / adverse effects
  • Hydroxychloroquine* / pharmacology
  • Hydroxychloroquine* / therapeutic use
  • Lupus Erythematosus, Systemic / drug therapy
  • Rheumatic Diseases / drug therapy
  • Sjogren's Syndrome / drug therapy

Substances

  • Hydroxychloroquine
  • Antirheumatic Agents
  • Antimalarials